Click Therapeutics’ CT-132 For Migraine Relief Earns FDA’s Breakthrough Device Designation

Click Therapeutics, Inc. (Click), a leader in Digital Therapeutics™ as prescription medical treatments, received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132. The device is a prescription digital therapeutic under development as an adjunctive preventive treatment for episodic migraine in those aged 18 years and older.

The Breakthrough Devices Program is intended for devices that have potential to provide for more effective treatment over existing standard of care for life-threatening or irreversibly debilitating diseases. The program is designed to expedite the development and review of medical devices meeting Breakthrough criteria in the . . .